Detalles de la búsqueda
1.
Unincreased mortality of patients with early rheumatoid arthritis compared to the general population in the past 17 years: Analyses from the IORRA cohort.
Mod Rheumatol
; 34(2): 322-328, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36786480
2.
Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI).
Mod Rheumatol
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727535
3.
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Mod Rheumatol
; 34(2): 297-306, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37233722
4.
Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database.
Mod Rheumatol
; 33(3): 496-502, 2023 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35652691
5.
Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database.
Mod Rheumatol
; 33(5): 899-905, 2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094815
6.
Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis.
Mod Rheumatol
; 34(1): 27-36, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36629510
7.
Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study.
Mod Rheumatol
; 2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37624029
8.
Evaluation of RABBIT risk score in Japanese patients with rheumatoid arthritis starting first bDMARDs: a validation study using the IORRA cohort data.
Mod Rheumatol
; 2023 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37409749
9.
Trends in risks of malignancies in Japanese patients with rheumatoid arthritis: Analyses from a 14-year observation of the IORRA cohort.
Mod Rheumatol
; 33(4): 715-722, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920098
10.
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Mod Rheumatol
; 34(1): 45-49, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36680420
11.
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate.
Mod Rheumatol
; 34(1): 37-44, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36680426
12.
Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication.
Mod Rheumatol
; 33(1): 36-45, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35294030
13.
Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication.
Mod Rheumatol
; 33(1): 21-35, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35297492
14.
Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.
Mod Rheumatol
; 33(2): 271-278, 2023 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35389481
15.
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Rheumatology (Oxford)
; 61(11): 4273-4285, 2022 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35136990
16.
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Mod Rheumatol
; 32(4): 718-727, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918129
17.
Impact of concomitant chronic kidney disease on hospitalised infections and remission in patients with rheumatoid arthritis: results from the IORRA cohort.
Mod Rheumatol
; 32(5): 875-884, 2022 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34751783
18.
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
Mod Rheumatol
; 32(4): 675-685, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918127
19.
Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids.
Mod Rheumatol
; 32(3): 522-527, 2022 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897494
20.
Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
Mod Rheumatol
; 32(1): 74-86, 2022 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33706664